# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002

> **NCT04677933** · PHASE1 · COMPLETED · sponsor: **OliPass Australia Pty Ltd** · enrollment: 30 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** A: OLP-1002
- **DRUG:** B: OLP-1002
- **DRUG:** C: Placebo

## Key facts

- **NCT ID:** NCT04677933
- **Lead sponsor:** OliPass Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-03
- **Primary completion:** 2020-12-22
- **Final completion:** 2020-12-22
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677933, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04677933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*